Barinthus Biotherapeutics plc (BRNS:NASDAQ) closed at $0.740 on September 8, 2026, down 2.49% on the day. The stock trades 59.6% below its 52-week high of $1.83 and 44.6% above its 52-week low of $0.512. Barinthus Biotherapeutics plc is part of the Health Care sector.
In 252 trading sessions since October 16, 2025, BRNS closed higher on 99 days (39%). Its best day was April 2, 2026 (+11.11%) and its worst was November 10, 2025 (-17.76%). The stock moved 10% or more in a single session 7 times. It opened at least 5% above the previous day's high 8 times.
Vaccitech PLC is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. Its therapeutic programs include VTP-300, VTP-200, VTP-850, and VTP-600. Its current prophylactic programs include VTP-400. In addition, it also co-invented a COVID-19 vaccine candidate with the University of Oxford known as COVID-19 Vaccine AstraZeneca.
Find more stocks like BRNS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.